NeuroSense Therapeutics has entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on August 16, 2024, enabling the company to offer and sell ordinary shares with aggregate gross proceeds of up to $2.52 million. The offering will be made under the company's existing shelf registration statement on Form F-3.Under the agreement, JonesTrading will serve as the sales agent, receiving a 3.0% commission on gross proceeds. The shares will be sold through various methods including at-the-market offerings on Nasdaq Capital Market or negotiated transactions at prevailing market prices. The company maintains flexibility with no obligation to sell shares.The agreement includes customary terms and conditions, with sales terminating upon either party's termination or mutual agreement. The offering is subject to satisfaction of certain conditions and will be conducted in compliance with applicable securities laws and regulations.

NeuroSense Therapeutics has entered into a Capital on Demand™ Sales Agreement with JonesTrading Institutional Services LLC on August 16, 2024, enabling the company to offer and sell ordinary shares with aggregate gross proceeds of up to $2.52 million. The offering will be made under the company's existing shelf registration statement on Form F-3.Under the agreement, JonesTrading will serve as the sales agent, receiving a 3.0% commission on gross proceeds. The shares will be sold through various methods including at-the-market offerings on Nasdaq Capital Market or negotiated transactions at prevailing market prices. The company maintains flexibility with no obligation to sell shares.The agreement includes customary terms and conditions, with sales terminating upon either party's termination or mutual agreement. The offering is subject to satisfaction of certain conditions and will be conducted in compliance with applicable securities laws and regulations.